U.S. Food and Drug Administration | MIDD Training Module 4 – Case Study 2: Anti-Viral Kinetic Modeling @US_FDA | Uploaded 2 months ago | Updated 14 hours ago
This lecture by Dr. Rajesh Krishna is a case study showing how anti-viral kinetic modeling can be used to support drug development (e.g., dose optimization).
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.
This lecture by Dr. Rajesh Krishna is a case study showing how anti-viral kinetic modeling can be used to support drug development (e.g., dose optimization).
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.
